Epoqe Pharma ApS
CVR 42443670 · Private limited company (ApS) · Active · Medium risk
Epoqe Pharma ApS is a Private limited company (ApS), founded on , based in Frederiksberg. The company is registered in the industry forskning og eksperimentel udvikling inden for naturvidenskab og teknik. Our model estimates a bankruptcy risk of 1.8% over the next 12 months, which is 1.3 times the average for Danish companies. 4 annual reports have been published. The latest annual report (31 Dec 2025) shows equity of DKK 44.1m and a net result of DKK -9.1m.
Bankruptcy risk for Epoqe Pharma ApS
1.3 × the average (1.41%) · higher risk than 81% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 42443670
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (5 years)
- Address
- c/o Symbion Frederiksberg, Nordre Fasanvej 215
2000 Frederiksberg - Municipality
- Frederiksberg
- Industry
- Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)
Bankruptcies in the industry: Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik - Share capital
- DKK 400k
- Auditor
- PKF Munkebo Eriksen Funch, Statsautoriseret Revisionsaktieselskab
- Audit opted out
- No
Warning signs
| Annual reports filed late | 0 of 4 |
| Missing annual report | No |
| Negative equity | No |
| Equity ratio | 86.2% |
| Current ratio | 724% |
| Moves (last 2 years) | 0 |
| CEO changes in total | 3 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 111 |
| Going-concern uncertainty | No |
Financials and key figures
| Financial year | 2025 | 2025 | 2024 |
|---|---|---|---|
| Gross profit | DKK -8.6m | DKK -13.7m | DKK 1.3m |
| Net profit | DKK -9.1m | DKK -13.9m | DKK -136k |
| Equity | DKK 44.1m | DKK 30.0m | DKK -18k |
| Total assets | DKK 49.2m | DKK 34.9m | DKK 1.1m |
| Cash | DKK 43.6m | DKK 30.2m | – |
| Short-term debt | DKK 5.0m | DKK 4.8m | – |
| Avg. employees | 3 | 3 | – |
Latest annual report: Reporting class B · auditor's statement: Revisionspåtegning · PKF Munkebo Eriksen Funch, Statsautoriseret Revisions aktie selskab.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jul 2024 – 30 Jun 2025 | 77 | ||
| 1 Jul 2023 – 30 Jun 2024 | 17 | ||
| 1 Jul 2022 – 30 Jun 2023 | 109 | ||
| 4 Jun 2021 – 30 Jun 2022 | 120 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Anette Sams Nielsen | ||
| CEO | Jens Thostrup Bukrinski | ||
| Board | Anders Gaarsdal Holst | Current | |
| Board | Henrijette Elsebeth Richter | Current | |
| Board | Lars Gredsted | Current | |
| Board | Mark Stephen Sumeray | Current | |
| Board | Anders Gaarsdal Holst | ||
| Board | Jan Bjerrum Bach | ||
| Board | Alejandra Maria Cristina Bonifacini Mørk | ||
| Board | Henrijette Elsebeth Richter | ||
| Board | Anette Sams Nielsen | ||
| Owner (5%) | Edvince ApS | Current | |
| Owner (33%) | LUNDBECKFOND INVEST A/S | Current | |
| Owner (5%) | Helms & Sams ApS | Current | |
| Owner (5%) | CMCGreenhouse ApS | Current | |
| Owner (33%) | Sofinnova Capital X | Current | |
| Owner (50%) | Helms & Sams ApS | ||
| Owner (50%) | Edvince ApS | ||
| Owner (50%) | Biologik ApS | ||
| Owner (33%) | Edvince ApS | ||
| Owner (33%) | Biologik ApS | ||
| Owner (5%) | Thomsen Pharma ApS | ||
| Owner (25%) | CMCGreenhouse ApS | ||
| Owner (20%) | Edvince ApS | ||
| Owner (33%) | Helms & Sams ApS | ||
| Owner (15%) | Helms & Sams ApS | ||
| Owner (10%) | CMCGreenhouse ApS | ||
| Owner (33%) | Sofinnova Capital X | ||
| Owner (20%) | LUNDBECKFOND INVEST A/S | ||
| Owner (20%) | LUNDBECKFOND INVEST A/S | ||
| Owner (10%) | Helms & Sams ApS | ||
| Owner (5%) | CMCGreenhouse ApS | ||
| Owner (33%) | Sofinnova Capital X | ||
| Auditor | PKF Munkebo Eriksen Funch, Statsautoriseret Revisionsaktieselskab | Current | |
| Founder | Helms & Sams ApS | Current | |
| Founder | Edvince ApS | Current |
The CEOs' other companies
Anette Sams Nielsen – 4 other companies
- Biologik ApS Active
- Helms & Sams ApS Active
- Helms & Sams Natur ApS Active
- RELIASSET A/S Active
Address history (2 moves)
| c/o Symbion Frederiksberg, Nordre Fasanvej 215, 2000 Frederiksberg | |
| Ole Maaløes Vej 3, 2200 København N | |
| Langs Hegnet 88, 2800 Kongens Lyngby |
Former names
| Epoqe Pharma ApS | – now |
| Patentselskabet af 31. maj 2021 ApS. | – |
Other companies at the same address
- Nordetect ApS Bankrupt
- ACESION PHARMA ApS Active
- AdaptVac ApS Active
- Adcendo ApS Active
- Akylox Therapeutics ApS Active
- Antraka ApS Opløst
- Augustine Therapeutics Denmark ApS Active
- Autocert ApS Active
- Avancert ApS Active
- B4C ApS Active
- BOOST Pharma ApS Active
- Baekmark IP Consult ApS Active
- Betula Capital ApS Active
- BioPhenyx ApS Active
- Biobridge Partners ApS Active
- Biotinia ApS Active
- CMCAssist ApS Active
- CMCGreenhouse ApS Active
- CMCHoldings ApS Active
- CaMaRa ApS Active
- Catalyst Vaccination A/S Active
- Chris Cording Jønsson Holding ApS Active
- DARERL ApS Active
- DFY ApS Active
- DeltaBot ApS Active
Similar companies in Frederiksberg
- Catalyst Vaccination A/S Frederiksberg
- RefuelBio ApS Frederiksberg
- BioMomentum Advisors ApS Frederiksberg
- Oak Mountain Consulting ApS Frederiksberg
- Biotinia ApS Frederiksberg
- Nordic BioVentures ApS Frederiksberg C
- Zevra Denmark A/S Frederiksberg
- BioPhenyx ApS Frederiksberg
- BioSpringbok ApS Frederiksberg
- Orbis Medicines ApS Frederiksberg
- SJM IP ApS Frederiksberg C
- Pephexia Therapeutics ApS Frederiksberg
Questions and answers about Epoqe Pharma ApS
Has Epoqe Pharma ApS gone bankrupt?
No, Epoqe Pharma ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of Epoqe Pharma ApS?
Our model estimates a bankruptcy risk of 1.8% over the next 12 months (medium risk), which is 1.3 times the average for Danish companies.
Who is the auditor of Epoqe Pharma ApS?
Epoqe Pharma ApS most recently used PKF Munkebo Eriksen Funch, Statsautoriseret Revisionsaktieselskab.
When was Epoqe Pharma ApS founded?
Epoqe Pharma ApS was founded on 4 June 2021.
What is the equity of Epoqe Pharma ApS?
Equity was DKK 44.1m according to the annual report for the period ending 31 December 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.